LOADING

Type to search

Thought Leadership Higher Education

Emory among U.S. sites hosting new clinical trial for COVID-19 treatment

Avatar
Nadine Rouphael, is interim director of the Hope Clinic, The Emory Vaccine Center. She is seen here providing treatment in an earlier clinical trial.
Featured Image: Nadine Rouphael, is interim director of the Hope Clinic, The Emory Vaccine Center. She is seen here providing treatment in an earlier clinical trial.

Emory University is taking part in global clinical trial to evaluate the safety and efficacy of novel therapeutic agents in hospitalized adult patients diagnosed with COVID-19. The drug remdesivir is the first agent to be evaluated.

The Emory Vaccine Treatment and Evaluation Unit (VTEU) was activated last week by The National Institute of Allergy and Infectious Diseases (NIAID), meaning it can begin enrollment as part of this phase three therapeutic clinical trial.

Aneesh Mehta, MD, is Emory principal’s investigator for the study of remdesivir.

Emory is one of several sites around the nation activated for the trial. The study will be conducted in up to 75 sites globally. Dr Aneesh Mehta, an investigator in both the national VTEU network and National Ebola Training and Education Center (NETEC), serves at the Emory principal investigator for this study. The Emory VTEU is led by Drs. Nadine Rouphael, Evan Anderson and Carlos Del Rio.

“This important study will allow our patients to access the highest level clinical care, driven by the best data from around the world, while contributing to the science of caring for patients with COVID-19,” says Mehta.

COVID-19 starts as an upper respiratory tract infection, often indistinguishable from other more common respiratory tract infections. First detected in Wuhan, China, the novel coronavirus has spread rapidly around the globe. Worldwide, the number of COVID-19 cases has topped 100,000, while in the United States the total has grown to more than 1,000.

Emory is playing a key role in the effort to expedite clinical trials to combat COVID-19. VTEUs have performed high-quality clinical research for more than half a century to test new vaccines and therapies for infectious diseases in clinical trials of adults and children. The Emory VTEU includes the Hope Clinic of the Emory Vaccine Center and the Emory Children’s Center Vaccine Research Clinic, both renowned in clinical and translational research in infectious diseases vaccines, treatment and prevention.

David S. Stephens, MD, professor and chair of the Department of Medicine in Emory University School of Medicine and vice president for research of Emory’s Woodruff Health Sciences Center, is the co-principal investigator of the Infectious Diseases Clinical Research Consortium, which is overseeing clinical trials of possible COVID-19 vaccines and treatments.

The VTEUs are a component of the Infectious Diseases Clinical Research Consortium (IDCRC). The IDCRC principal investigators are David S. Stephens, MD, professor and chair of the Department of Medicine in Emory University School of Medicine and vice president for research of Emory’s Woodruff Health Sciences Center, and Kathy Neuzil, MD, Myron M. Levine MD Professor in Vaccinology and director, Center for Vaccine Development, University of Maryland Baltimore.

“This COVID-19 outbreak is expanding rapidly,” says Stephens. “Thanks to the foresight of the NIAID we have a critical infrastructure in place to move quickly as well, harnessing some of the brightest minds in the academic medical community to fight COVID-19.”

The clinicaltrials.gov identifier is NCT04280705.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.